Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant Borrel virus combined vaccine

A fowlpox virus and vaccine technology, applied in antiviral agents, antibody medical ingredients, medical preparations containing active ingredients, etc., can solve the problems of reducing vaccine immune protection and low attack protection

Inactive Publication Date: 2007-08-08
YANGZHOU UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

We used the FPV vector to construct the rFPV vector co-expressing the gB gene of Marek's disease virus and chicken type II interferon gene. Compared with the rFPV expressing MDV gB alone, the 1-day-old immunization test chicken also significantly reduced the rate of FPV weight loss. Side effects, reaching the level of weight gain of healthy controls, but its protection against the virulent Marek's disease virus is lower than that of rFPV with single expression of MDV gB, indicating that although the co-expression of type II interferon increases the efficacy of rFPV genetic engineering vaccine Safety, but also reduces the immune protection of the vaccine, which may not be worth the candle

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant Borrel virus combined vaccine
  • Recombinant Borrel virus combined vaccine
  • Recombinant Borrel virus combined vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Embodiment 1 Amplification, cloning and sequence analysis of chicken type II interferon gene

[0057] Culture of Chicken Spleen Lymphocytes

[0058] Aseptically take the chicken spleen according to the conventional method, put it in 5ml PBS, squeeze and collect the splenocytes, add the same amount of layered liquid of lymphocytes under the PBS liquid containing splenocytes, centrifuge at 1500rpm for 20min at room temperature, and collect at the interface After counting, add culture medium (DMEM containing 5% calf serum, glutamine containing 2mmol / L, HEPES 10mmol / L, concanavalin A (ConA) of 5μg / L) to adjust the splenocyte concentration to 10 7 Units / ml, placed at 41°C, 5% CO 2 Conditioned for 16h.

[0059] Extraction of total RNA containing interferon mRNA

[0060] Take 1ml of the chicken spleen lymphocytes cultured above (about 10 7 cells), placed in a 1.5ml centrifuge tube, centrifuged at 2500rpm for 10 minutes at 4°C, discarded the supernatant, added 1ml of TRIzo...

Embodiment 2

[0068] Example 2 Construction of FPV transfer vector (1175IFN) containing cIFN-II gene

[0069] The construction strategy of FPV transfer vector 1175IFN containing cIFN-II gene is shown in Figure 4.

[0070] After the above-mentioned steps in Example 1, in order to add the FPV early and late promoters in front of the cIFN-II gene sequence and smoothly connect to the FPV insertion vector 1175, the following four steps of conversion were performed.

[0071] First, pIFN was digested with SalI and HindIII to recover the cIFN-II gene fragment and inserted into the PE / L-containing pAF09 digested with SalI and HindIII to obtain a recombinant plasmid (AIFN). In AIFN, cIFN-II is located in the early and late stages of vaccinia virus Downstream of the promoter PE / L (Figure 5); followed by using the AIFN plasmid as a template to design a pair of primers

[0072] P3: 5'CCT GTC GAC AGC CAT TTA AGT ATC CCT AA 3’

[0073] P4: 5'GCG GTC GAC AAA AAA AAC TAT TAG CAA TTG CAT CTC CTC 3'),...

Embodiment 3

[0074] Embodiment 3 transfection and purification

[0075] The 1175IFN plasmid obtained in Example 2 was extracted in large quantities by alkaline lysis method, and the plasmid was purified by PEG method, OD 260 After determining the DNA content, fill it with ultra-pure water to make it 1 μg / ml for later use. DMEM containing 4% calf serum by 10 7cells / ml to prepare CEF, add 5ml of the above cell solution to each 100ml square bottle, and incubate at 37°C for 18h; then add wtFPV at an infection rate of 0.1 MOI, and adsorb at 37°C for 3h; wash the CEF monolayer twice with serum-free DMEM, Then add 2ml of serum-free DMEM for later use. Dilute 50 μg liposome transfection reagent (Dosper Lipofectin, Roche Company) and 10 μg 1175IFN to 50 μl in two 1.5ml finger tubes respectively, and the weight ratio of liposome and plasmid DNA is 5:1, and the above two tubes The substances were mixed, mixed gently, and allowed to stand at room temperature for 15 minutes. Then add the above-ment...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to recombinant fowl pos virus (rFPV) to express fowl type-II interferon and rFPV combined animal vaccine to express the antigen gene of different pathogene. The present invention also relates to the method of maintaining and reinforcing vaccine protection capacity and includes the method of mixing rFPV of expressing other cell factor and rFPV as the protecting antigen gene of vaccine dosage expressing antigen to obtain animal vaccine. The vaccine can reduce the harmful side effect of FPV, especially the side reaction of affecting weight increase of the immunized animal.

Description

technical field [0001] The invention relates to a recombinant fowlpox virus vaccine, in particular to a combined vaccine of a recombinant fowlpox virus expressing chicken type II interferon and a recombinant fowlpox virus expressing a pathogen protective antigen gene. Background technique [0002] Fowl pox virus (FPV) is a member of the genus Fowlpoxvirus in the family Poxviridae. The core of the virion contains double-stranded linear DNA, G+C=35%, and the length of the genome is about 300kb. FPV DVA is not infectious . Through recombinant DNA technology, using FPV as a carrier to develop poultry genetically engineered recombinant live virus vector vaccines, or mammalian non-replicating recombinant live virus vector vaccines has attracted more and more attention from researchers. Compared with the reported viral vectors such as vaccinia virus, papilloma virus, adenovirus, parvovirus, Marek's disease virus, tobacco mosaic virus, FPV vector has obvious advantages. The genome...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/275A61P31/12
Inventor 刘秀梵彭大新程坚吴艳涛王志亮高崧甘军纪文其乙
Owner YANGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com